Tasa de mortalidad por Tumor Maligno de Hígado en Chile (2016-2024)

Alison Alanoca Paton; Sebastián Zúñiga Pizarro; Jose Arias Cruz; Natalia Benítez Herrera; Jhonatan Cahuasiri Cavero

doi:10.5281/zenodo.20173348

Authors

Alison Alanoca Paton Médico Cirujano, Hospital de Alto Hospicio, Chile Author https://orcid.org/0009-0007-4657-0489
Sebastián Zúñiga Pizarro Médico Cirujano, Hospital de Alto Hospicio, Chile Author https://orcid.org/0009-0003-0286-4865
Jose Arias Cruz Médico Cirujano, Hospital de Alto Hospicio, Chile Author https://orcid.org/0009-0005-4257-9502
Natalia Benítez Herrera Médico Cirujano, Hospital de Alto Hospicio, Chile Author https://orcid.org/0009-0000-7768-8569
Jhonatan Cahuasiri Cavero Médico Cirujano, Hospital de Alto Hospicio, Chile Author https://orcid.org/0009-0002-9166-0508

DOI:

https://doi.org/10.5281/zenodo.20173348

Keywords:

Chile, Mortality, Oncology, Hepatocellular Carcinoma

Abstract

Introduction: Malignant liver tumor, classified as hepatocellular carcinoma, constitutes one of the leading causes of cancer-related death worldwide. Objective: To calculate the mortality rate from malignant liver tumor during the period from 2016 to 2024 in Chile. Methodology: An observational, descriptive, and quantitative study was conducted using statistical data from the Department of Health Statistics and Information (DEIS) regarding deaths classified under the ICD-10 code “CC22.0” (hepatocellular carcinoma) occurring in Chile, along with demographic information from the 2024 Population and Housing Census. Results: The highest mortality rate (MR) occurred in 2024, with 9.13 deaths per-100,000 inhabitants. Males presented the highest MR during the study period, with 8.45 deaths per-100,000 inhabitants. The age group over 80 years showed the highest mortality, with 62.06 deaths per-100,000 inhabitants. Discussion: The increase in MR during 2024 could be associated with population aging and an increase in metabolic risk factors. Males showed higher mortality, probably attributable to a greater number of risk factors, such as alcoholism and cirrhosis. The group over 80 years presented the highest MR of the period, which could be due to the accumulation of chronic liver damage related to epidemiological factors such as cirrhosis and non-alcoholic liver disease. Conclusion: A high-risk group is evident, demonstrating the need to improve public policies aimed at controlling risk factors and promoting early diagnosis.

Downloads

Download data is not yet available.

References

1. Liu H, Bruner ET, Yang J. Cytologic features of malignant rhabdoid tumor of the liver: a case report and literature review. Diagn Cytopathol. 2021;49(9):E364-E369. Disponible en: https://doi.org/10.1002/dc.24815

2. Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6. PMID: 33479224. Disponible en: http://doi.org/10.1038/s41572-024-00500-6

3. Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022 Oct 15;400(10360):1345-1362. Disponible en: https://doi.org/10.1016/s0140-6736(22)01200-4

4. El-Serag HB. Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2020;24(4):537-555. PMID: 32866476. Disponible en: https://doi.org/10.1016/s1089-3261(05)70155-0

5. Ganesan P, Kulik LM. Hepatocellular Carcinoma: New Developments. Clin Liver Dis. 2023 Feb;27(1):85-102. Disponible en: https://doi.org/10.1016/j.cld.2022.08.004

6. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301-1314. PMID: 29307467. Disponible en: https://doi.org/10.1016/s0140-6736(18)30010-2

7. Alawyia B, Constantinou C. Hepatocellular Carcinoma: a Narrative Review on Current Knowledge and Future Prospects. Curr Treat Options Oncol. 2023 Jul;24(7):711-724. Disponible en: https://doi.org/10.1007/s11864-023-01098-9

8. May P, Normand C, Cassel JB, Del Fabbro E, Fine RL, Menz R, Morrison CA, Penrod JD, Robinson C, Morrison RS. Economics of Palliative Care for Hospitalized Adults With Serious Illness: A Meta-analysis. JAMA Intern Med. 2018 Jun 1;178(6):820-829. Disponible en: https://doi.org/10.1001/jamainternmed.2018.0750

9. Younossi ZM, Stepanova M, Younossi Y, et al. Epidemiology of NAFLD and NASH globally. Hepatology. 2019;69(1):273-284. PMID: 30179255. Disponible en: https://doi.org/10.1016/j.jhep.2019.06.021

10. Gilles H, Garbutt T, Landrum J. Hepatocellular Carcinoma. Crit Care Nurs Clin North Am. 2022 Sep;34(3):289-301. Disponible en: https://doi.org/10.1016/j.cnc.2022.04.004

11. Toh MR, Wong EYT, Wong SH, Ng AWT, Loo LH, Chow PK, Ngeow J. Global Epidemiology and Genetics of Hepatocellular Carcinoma. Gastroenterology. 2023 Apr;164(5):766-782. Disponible en: https://doi.org/10.1053/j.gastro.2023.01.033

12. Kim D, Li AA, Gadiparthi C, Khan MA, Cholankeril G, Glenn JS, Ahmed A. Changing Trends in Etiology-Based Annual Mortality From Chronic Liver Disease, From 2007 Through 2016. Gastroenterology. 2018 Oct;155(4):1154-1163.e3. Disponible en: https://doi.org/10.1053/j.gastro.2018.07.008

13. Spector LG, Birch J. The epidemiology of hepatoblastoma. Pediatr Blood Cancer. 2012 Nov;59(5):776-9. Disponible en: https://doi.org/10.1002/pbc.24215

14. Nevola R, Tortorella G, Rosato V, Rinaldi L, Imbriani S, Perillo P, Mastrocinque D, La Montagna M, Russo A, Di Lorenzo G, Alfano M, Rocco M, Ricozzi C, Gjeloshi K, Sasso FC, Marfella R, Marrone A, Kondili LA, Esposito N, Claar E, Cozzolino D. Gender Differences in the Pathogenesis and Risk Factors of Hepatocellular Carcinoma. Biology (Basel). 2023 Jul 11;12(7):984. Disponible en: https://doi.org/10.3390/biology12070984

15. Huang J, Wang HHX, Zheng ZJ, Wong MCS. Impact of the COVID-19 pandemic on cancer care. Hong Kong Med J. 2022 Dec;28(6):427-429. Disponible en: https://doi.org/10.12809/hkmj215136